AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.93+4.43 (+1.30%) ▲|ABBV284.67-4.41 (-1.53%) ▼|ABT100.56-1.89 (-1.84%) ▼|ACN240.28+1.16 (+0.49%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.63-5.93 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.64+5.30 (+1.66%) ▲|BA192.31+1.84 (+0.97%) ▲|BAC50.80+0.16 (+0.32%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.10+20.42 (+1.81%) ▲|BMY61.16-0.53 (-0.85%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B541.16+1.34 (+0.25%) ▲|C123.84+1.33 (+1.08%) ▲|CAT740.16+14.92 (+2.06%) ▲|CL93.42-1.13 (-1.19%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.49+4.93 (+2.44%) ▲|COP145.70-0.25 (-0.17%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.72-0.71 (-0.29%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.76+1.05 (+0.46%) ▲|DE636.56+4.36 (+0.69%) ▲|DHR234.02+9.78 (+4.36%) ▲|DIS111.82+0.15 (+0.13%) ▲|DUK120.69-0.64 (-0.53%) ▼|EMR163.13+2.67 (+1.66%) ▲|FDX298.18-0.58 (-0.19%) ▼|GD344.91+0.47 (+0.14%) ▲|GE295.84-4.04 (-1.35%) ▼|GEV926.39+36.06 (+4.05%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.10-0.99 (-1.28%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.50+19.69 (+2.23%) ▲|HD314.08-1.03 (-0.33%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.06+9.14 (+3.78%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.65-1.71 (-0.66%) ▼|JPM335.13-0.13 (-0.04%) ▼|KO92.68-0.82 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,272.20-11.46 (-0.89%) ▼|LMT551.97+3.26 (+0.59%) ▲|LOW196.55-0.73 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.50+2.08 (+0.33%) ▲|MCD246.22-0.30 (-0.12%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.69+3.32 (+1.94%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.89+1.59 (+1.07%) ▲|MS187.11+6.71 (+3.72%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.25-0.61 (-0.77%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.14+3.60 (+2.41%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.10-2.04 (-1.56%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.86-0.25 (-0.83%) ▼|PG156.89-2.43 (-1.53%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.47-2.43 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.29+6.92 (+1.01%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
17.3 C
New York
Wednesday, October 21, 2026

Tag: period

newsFORsourcecompanycontentinformation1releasesmarket

ROSEN, A LEADING LAW FIRM, Encourages Helen of Troy Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – HELE

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Helen of Troy Limited (NASDAQ: HELE) between April 24, 2024 and October 8, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Graphic Packaging Holding Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPK

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sportradar Group AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRAD

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A ordinary shares of Sportradar Group AG (NASDAQ: SRAD) between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

RGC DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities...

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

Inturai Ventures Announces Adoption of Semi-Annual Reporting

(CSE: URAI  / OTC: URAIF / FSE: 3QG0)                                                                                                    investor@inturai.comVANCOUVER, BC, June 5, 2026 /CNW/ - Inturai Ventures Corp. (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) (the...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WGS

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. (WGS)

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired GeneDx Holdings Corp. (“WGS” or the “Company”) (NASDAQ: WGS) securities between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Xsolis, Inc. Provides Notice of Data Security Incident

FRANKLIN, Tenn., June 5, 2026 /PRNewswire/ -- Xsolis, Inc. ("Xsolis"), a vendor that provides case and utilization management services to healthcare organizations, today announced...

HELE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Helen of Troy Limited. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Helen of Troy Limited (HELE) Misled Investors Regarding the Ability of Project Pegasus to Improve Efficiency

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPeriod

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers